The Role of High-Dose IL-2 in RCC

Clinical Pearls

Mario Sznol, MD, professor of medicine, Yale Cancer Center, discusses the role of high-dose IL-2 for the treatment of renal cell carcinoma (RCC).

• There is still a role for high-dose IL-2 in RCC.
• Anti-PD-1 agents are active, but a different population of patients may respond to high-dose IL-2.
• Both agents are necessary to achieve durable remissions.
• If combinations with anti-PD-1 agents prove to be active, IL-2 may be moved to the second- or third-line.